NCT03576521 is a Phase 2 clinical trial of CT + Ocoxin-Viusid in Breast Cancer, sponsored by Catalysis SL.

Who is sponsoring NCT03576521?

NCT03576521 is sponsored by Catalysis SL.

What drugs are being tested in NCT03576521?

Interventions in NCT03576521: CT + Ocoxin-Viusid, CT + Placebo.

What condition does NCT03576521 study?

NCT03576521 studies Breast Cancer, Breast Carcinoma, Adriamycin Toxicity, Cyclosporine Toxicity.

Is NCT03576521 still recruiting?

NCT03576521 is currently completed. Last updated 3 July 2018.

Last reviewed 2018-07-03 · How we verify

NCT03576521

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

Evaluation of Ocoxin®-Viusid® in Breast Cancer

Completed Phase 2 Last updated 3 July 2018

What this trial tests

Phase 2 trial testing CT + Ocoxin-Viusid in Breast Cancer in 120 participants. Completed in 19 February 2018.

Timeline

13 May 2015

Primary endpoint
1 January 2018

19 February 2018

Quick facts

Lead sponsor	Catalysis SL
Phase	Phase 2
Status	Completed
Study type	INTERVENTIONAL
Allocation	randomized
Design	parallel
Masking	triple
Primary purpose	supportive care
Enrollment	120
Start date	13 May 2015
Primary completion	1 January 2018
Estimated completion	19 February 2018
Sites	1 location across Cuba

Drugs / interventions tested

CT + Ocoxin-Viusid
CT + Placebo

Conditions studied

Breast Cancer — all drugs for Breast Cancer →
Breast Carcinoma — all drugs for Breast Carcinoma →
Adriamycin Toxicity — all drugs for Adriamycin Toxicity →
Cyclosporine Toxicity — all drugs for Cyclosporine Toxicity →

Sponsor

Catalysis SL — full company profile →

Who can join

18 and older, female only, with Breast Cancer or Breast Carcinoma. Patients with the condition only — healthy volunteers not accepted.

Sponsor's own description

The purpose is to determine the efficacy of the nutritional supplement Ocoxin-Viusid oral solution (OV) in the reduction of acute toxicity of Chemotherapy (CT) treatment with patients with breast carcinoma. A randomized, double-blind phase II clinical trial was designed, with a sample of 120 patients distributed in 2 arms: 60 patients will receive the CT treatment plus the OV, 60 will receive CT plus OV placebo. The OV / placebo will be administered before, during and 3 weeks after the conclusion of the CT. A better tolerance to the treatment is expected with the addition of the nutritional supplement.

Publications & conference data

No peer-reviewed publications indexed yet for this trial. Completed trials usually publish results within 12-18 months.

Verify or expand the search:

Other recruiting trials for Breast Cancer

Currently open trials in the same condition.

NCT06148038 — CBD for Breast Cancer Primary Tumors · Phase 1 · recruiting
NCT07405801 — A Phase II Study Evaluating the Efficacy and Safety of Inavolisib Plus Ribociclib Plus Fulvestrant Versus Placebo Plus R · Phase 2 · recruiting
NCT07285993 — Detection and Outcomes in Metastatic Invasive Lobular Breast Cancer Through Novel F-18 FAP PET · Phase 2 · recruiting
NCT07510698 — Same-Day Awake Mastectomy With Immediate Breast Reconstruction for Patients With Breast Cancer · NA · recruiting
NCT06768931 — Biolosion Combined Standard Neoadjuvant Therapy to Treat Triple-negative Breast Cancer · Phase 2 · recruiting

Other Catalysis SL trials

Trials by the same sponsor.

NCT07179237 — Efficacy of Carminal in Helicobacter Pylori Gastritis · Phase 2 · recruiting
NCT06363201 — Effect and Safety of Ocoxin Oral Solution on the Quality of Life of Paediatric Patients With Advanced Stage Solid Tumour · NA · not yet recruiting
NCT05916911 — Evaluation Of The Efficacy Of The Combination Of GLIZIGEN® Oral Solution 1/Day And Vaginal Gel 1/Night For 2 Months In P · Phase 4 · unknown
NCT06496087 — Evaluation of DEPREXIL in Patients With Clinical Depression Through Psychological and Neuroendocrine Assessment · NA · completed
NCT06361992 — Efficacy and Safety of Blue Cap for the Treatment of Atopic Dermatitis in Children · Phase 3 · completed

Verify against primary sources

ClinicalTrials.gov — authoritative US registry record
WHO ICTRP — international registry index
EU Clinical Trials Register
Sponsor press releases (Google)

Data sources for this page

Trial protocol + status: ClinicalTrials.gov NCT03576521 (US National Library of Medicine, public domain)
Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
Sponsor: as reported to ClinicalTrials.gov by Catalysis SL
Last refreshed: 3 July 2018

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT03576521.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing